A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

To join this study, you need to be an adult with a diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that needs treatment. You will also need to be at least 65 years old, OR if you are between 18 and 64, you have to meet at least one additional health condition, like certain kidney health scores or a specific illness rating.

Doctors will check your cancer to make sure it can be measured, for example, by looking at your lymph nodes on a scan. You also need to be well enough to take part in the study, with your daily activities not too limited by your illness.

You cannot join if you've already had medicine treatment for CLL or SLL. Also, if your cancer has a specific genetic change (called a 17p deletion or TP53 mutation above a certain level), or if you've had major surgery recently, you won't be able to participate. Bleeding problems or if your cancer has spread to your brain or spinal cord would also mean you can't join.

The detailed information about what taking part involves is not fully provided in this summary. However, generally, in studies like this, if you are eligible and agree to take part, you would be assigned to one of the two treatment groups. This would involve taking specific study medications, likely by mouth or through an injection/drip, for a set period. You would need to attend regular clinic visits for check-ups, blood tests, and scans to monitor your health and how well the treatment is working. The study team would explain the exact schedule of visits and tests. There would also be a follow-up period after your main treatment finishes to see how you are doing in the long term. The total duration of the study, including treatment and follow-up, would be fully explained by the study team.